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Purpose: Dichloroacetate (DCA) inhibits pyruvate dehydrogenase kinase (PDK), and thus 
  promotes glucose oxidation over glycolysis and induces apoptotic death of tumor cells. 
The   present study investigated the potential of DCA to increase the antitumor effects of 
  platinum-based compounds against a panel of permanent cell lines, including small cell lung 
cancer (SCLC), ovarian cancer, and Ewing’s sarcoma in vitro.
Methods: DCA at a concentration of 10 mM was combined with cisplatin, carboplatin,   satraplatin, 
the satraplatin metabolite JM118, oxaliplatin, oxoplatin, and picoplatin, and the cytotoxic activity 
was evaluated in proliferation tests employing a panel of different cell lines.   Additionally, cells 
were pretreated with DCA and then exposed to the platinum drugs and   etoposide, or incubated 
with cisplatin or etoposide followed by application of DCA, respectively.
Results: DCA 10 mM significantly increased the cytotoxicity of the platinum-based drugs 
carboplatin, satraplatin, JM118, and oxoplatin, but not cisplatin, picoplatin, and oxaliplatin 
in vitro. Preincubation of cell lines with DCA 10 mM for three days reduced the   antiproliferative 
activity of platinum-based agents in sequential application, but exposure of cells pretreated with 
cisplatin or etoposide to DCA resulted in minor sensitization. The inhibitory effect of DCA 
showed no correlation with sensitization to the platinum compounds.
Conclusion: DCA alone in a concentration that shows low antiproliferative activity is capable 
of increasing the cytotoxicity of selected platinum compounds upon coincubation, and such 
combinations may be interesting for clinical application in tumors like SCLC, Ewing’s sarcoma, and 
ovarian cancer refractory to cisplatin chemotherapy as standard care. The mechanism of this syner-
gistic effect of DCA in combination with specific platinum species remains to be investigated.
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Introduction
Unlike normal, untransformed cells, most cancer cells rely on aerobic glycolysis to 
gain energy, a phenomenon termed the “Warburg effect”.1 Since this is an   inefficient 
way to generate adenosine triphosphate, this metabolic switch is supposed to 
confer other important advantages on tumor cells, such as capability to modulate 
  intracellular/  extracellular pH, promote anabolic metabolism and, especially, the 
  glycolytic phenotype in cancer, which suppresses mitochondrial function and thus 
increases resistance to apoptotic cell death.2 This direction of glucose utilization may 
be diverted by the generic drug dichloroacetate (DCA), an orally active small molecule 
that, by inhibiting pyruvate dehydrogenase kinase (PDK), increases the flux of pyruvate 
into the mitochondria and thus promotes glucose oxidation over glycolysis.3 Inhibition 
of in vitro and in vivo tumor growth by DCA is attributed to depressed mitochondrial 
function and increased apoptosis.Clinical Pharmacology:  Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
178
Olszewski et al
DCA treatment promotes apoptosis in lung and breast 
cancer as well as glioblastoma cell lines by a shift in metabolism 
from aerobic glycolysis to glucose oxidation, coupled with 
tumor-specific decreases of membrane potential and activa-
tion of potassium channels in mitochondria.4 DCA-sensitive 
endometrial cancer cell lines treated with DCA 5–10 mM 
showed increased early and late apoptosis, decreased mito-
chondrial membrane potential and lower survivin transcript 
levels, consistent with a mitochondria-regulated mechanism.5 
Treatment of representative colorectal cancer cell lines with 
DCA 20 mM caused   significant decreases in cancer cell pro-
liferation associated with cell-cycle arrest in G2 phase and 
apoptosis, in contrast to noncancerous cell lines.6 The growth 
of several breast   cancer cell lines was found to be inhibited 
by DCA in   vitro.7   Furthermore, treatment of metastatic 
13762 MAT rat   mammary adenocarcinoma cells with DCA 
in vivo revealed that reversal of the glycolytic phenotype was 
correlated with inhibition of proliferation without affecting 
cell viability. These data demonstrate antiproliferative and 
proapoptotic properties for DCA, as well as antitumor activity 
against highly metastatic disease in vivo.
Although this drug seems generally safe, a clinical trial 
based on application of DCA 25 mg/kg/day was discontin-
ued early because patients with MELAS (Mitochondrial 
Encephalopathy, Lactic Acidosis, and Stroke-like episodes) 
under treatment developed peripheral neuropathy.8 DCA is 
a major byproduct of water disinfection by chlorination, and 
several studies have demonstrated hepatocarcinogenesis in 
mice after intake through drinking water.9
An important mechanism of resistance acting downstream 
of the uptake of cisplatin and DNA adduct formation is 
decreased induction of apoptosis and, therefore, DCA-  induced 
sensitization of cancer cells to this form of cell death is 
expected to overcome resistance partially.10 In an attempt to 
increase the cytotoxicity of cisplatin, a derivative was syn-
thesized by coordination of two DCA molecules to the axial 
positions of this drug, yielding the platinum (IV) compound 
mitaplatin.11 This drug is cleaved in the cytoplasm, and the 
separated agents, cisplatin and DCA, attack nuclear DNA 
and mitochondria, respectively. The cytotoxicity of mitaplatin 
in a variety of cancer cell lines equals or exceeds that of all 
known platinum (IV) compounds and is comparable with that 
of cisplatin, partially overcoming drug resistance. However, 
with the use of mitaplatin, the platinum:DCA stoichiometry 
is invariably 1:2, with simultaneous application and DCA 
concentrations in tumor tissue in the subnanomolar range.12 
Data on the intracellular concentration of DCA are lacking, 
but it is known that inhibition of the four isoforms of PDK as 
observed in treated cells requires the presence of DCA in the 
0.2–8 mM Ki range.13 Moreover, several problems still remain 
to be addressed regarding the most suitable platinum agent for 
combination with DCA, as well as the optimal concentration 
and sequence of DCA application. The effects of DCA on the 
mitochondrial membrane potential, cell viability, and induc-
tion of apoptosis were evaluated in pediatric tumor cell lines 
and in the nonmalignant cell line, HEK293.14 Concentrations 
of DCA #10 mM only moderately inhibited growth of the 
cell lines, but the toxicity of cisplatin was abrogated in most 
cell lines, without effects on cisplatin stability and uptake.
We found in our laboratory that DCA acts synergisti-
cally with several platinum drugs, but not with cisplatin, 
in a chemoresistant human pulmonary carcinoid cell line.15 
Therefore, this research was extended, and included combi-
nations of DCA with a range of newer platinum drugs and 
different modes of sequential application in a larger panel 
of cancer cell lines and in HEK293.
Materials and methods
Chemicals and cell lines
Unless otherwise noted, all chemicals and solutions were 
obtained from Sigma-Aldrich (St. Louis, MO). Satraplatin 
[bisacetatoammine dichloro cyclohexylamine platinum (IV)], 
JM118 [cis-ammine dichloro cyclohexylamine platinum (II)], 
oxoplatin [cis,cis,trans-diammine dichloro dihydroxo platinum 
(IV)], and picoplatin ([cis-ammine dichloro 2-methylpyridine 
platinum (II)] were custom synthesized. A 1 M stock solution 
of sodium DCA was prepared by dissolution in phosphate-
buffered saline. Cell lines were purchased from the American 
Tissue Culture Collection (ATCC, Manassas, VA) or the 
European Collection of Cell Cultures (ECACC, Porton 
Down, Salisbury, UK), respectively, and the Ewing’s sarcoma 
and HEK293 cells were obtained from Dr T Thalhammer 
(Institute of Pathophysiology, University School of Medicine, 
Vienna, Austria). Cells were cultured in RPMI-1640 medium 
supplemented with 10% fetal bovine serum (Seromed, Berlin, 
Germany), 4 mM glutamine, and antibiotics. HEK293, 
UMC-11, ES-2, and COLO 205 cells were subcultured by 
trypsinization (2.5% trypsin/  ethylenediaminetetraacetic acid 
solution; Boehringer Mannheim, Germany), and TC71 and 
TC252 cells were detached using Ca2+/Mg2+-free phosphate-
buffered saline.
Cell proliferation assay
Cells were harvested, counted, and distributed into the wells 
of flat-bottomed 96-well microtiter plates at a density of 
1 × 104 cells/well in 100 µL medium; 100 µL of appropriate Clinical Pharmacology:  Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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dilutions of test compounds were added to each well and 
plates incubated under tissue culture conditions for four days. 
Stock solutions of the compounds were prepared in either 
70% ethanol or dimethyl sulfoxide, respectively, and diluted 
more than 100-fold for use in chemosensitivity assays. Solvent 
control wells were included in all tests. Dose-response curves 
were obtained by assessment of cell growth at twofold drug 
dilutions in triplicate and used for calculation of the IC50 half 
maximal inhibitory concentration values. Cell proliferation 
was quantified using a modified tetrazolium dye assay (MTT; 
EZ4U, Biomedica, Vienna, Austria) by measurement of the 
absorbance of the resulting dye at a wavelength of 450 nm 
(medium/solvent control set to 100% proliferation).
statistical analysis
IC50 values and corresponding ratios were calculated from 
dose-response curves of the chemosensitivity assays performed 
in triplicate. A value of P , 0.05 was regarded as statistically 
significant in t-tests. All calculations were performed using 
Winks statistical software (Texasoft, Duncanville, TX).
Results
According to the literature and our conclusions from initial 
titration experiments, concentrations of DCA below and 
exceeding 10 mM resulted in insufficient activity or antagonistic 
growth inhibition when combined with chemotherapeutics, 
respectively, and, therefore, a DCA concentration of 10 mM 
was used in all further experiments. The results of experiments 
investigating the cytotoxicity of a large panel of platinum 
drugs and etoposide in combination with 10 mM DCA against 
DMS153 small cell lung cancer (SCLC) cells are shown in 
Figure 1. DCA alone inhibited the growth of DMS153 cells 
by 22.5% ± 6.1%. Inclusion of DCA had minor effects on the 
activity of cisplatin [cis-diammine dichloroplatinum (II)], oxali-
platin [1R,2R-diaminocyclohexane oxalato platinum (II)], and 
picoplatin, whereas the IC50 values of carboplatin [cis-diammine 
(1,1-cyclobutane dicarboxylato) platinum (II)], satraplatin, the 
satraplatin metabolite JM118, and oxoplatin were significantly 
lowered, indicating considerable sensitization of the cells to 
selected platinum complexes. In addition, etoposide showed 
increased cytotoxicity in the presence of DCA. In a similar 
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Figure 1 sensitization of DMs 153 sCLC cells by either combined treatment with DCA 10 mM and platinum drugs or following pretreatment of cells with DCA 10 mM 
(mean ± standard deviation). For combined treatment, all ratios show significant effects, except for cisplatin and picoplatin; for pretreatment, all ratios show significant effects, 
except for JM118 and etoposide.Clinical Pharmacology:  Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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set of experiments, DMS153 SCLC cells were pretreated with 
DCA 10 mM in tissue culture for three days and thereafter 
tested for their chemosensitivity against the same compounds 
as described above (Figure 1). With the exception of JM118 and 
etoposide, all other drugs proved to be less effective, yielding 
IC50 values that were increased by approximately 100%. Similar 
results were found for the DCA-preincubation experiments 
using the NCI-H417 SCLC cell line (11.0% ± 7.1% inhibition 
by DCA alone). Hence, with the exception of oxoplatin 
(sensitization ratio 1.16 ± 0.03) and etoposide (0.85 ± 0.17), all 
other compounds revealed lower toxicity (cisplatin 0.56 ± 0.22, 
carboplatin 0.32 ± 0.04, oxaliplatin 0.69 ± 0.15, satraplatin 
0.84 ± 0.24, JM118 0.16 ± 0.07, and picoplatin 0.69 ± 0.27). 
Therefore, pretreatment of the two SCLC lines with DCA 
10 mM reduced the chemosensitivity of the subsequently 
applied platinum drugs.
Typical dose-response curves for combinations of 
cisplatin and satraplatin, respectively, with DCA 10 mM are 
shown in Figure 2 for the ES-2 ovarian clear cell carcinoma 
cell line. The platinum compounds were applied in twofold 
dilution steps concurrent with DCA 10 mM (13.0% ± 0.21% 
inhibition as a single agent) for in vitro testing of this cell 
line with an incubation time of four days. Whereas the 
cytotoxicity of cisplatin remained unchanged, the activity of 
satraplatin was significantly increased by almost fourfold.
An overview of the results of chemosensitivity tests using 
combinations of DCA with cisplatin, carboplatin, satraplatin, 
and JM118, involving a panel of different cell lines is presented 
in the Table 1. DCA at a concentration of 10 mM inhibited the 
growth of most of the cell lines by up to approximately 22%, 
with minor effects on a colon cancer and two carcinoid cell 
lines, as well as growth stimulation in TC252 Ewing’s sarcoma 
cells. The cytotoxic activity of cisplatin was elevated in 1/9, 
carboplatin in 4/9, satraplatin in 8/9, and JM118 in 7/9 of the 
cell lines, respectively. In   contrast to the other three platinum 
complexes, cisplatin in   combination with DCA exhibited 
lower cytotoxicity against HEK293 normal epithelial kidney 
cells. H835 carcinoid cells growing as floating spheroids were 
unique in that they showed increased resistance to cisplatin, 
satraplatin, and JM118, when   combined with DCA. For the 
cell lines under investigation, the inhibitory effect of DCA on 
cell proliferation revealed no correlation with sensitization to 
the chemotherapeutic drugs.
In preliminary experiments, the cytotoxicity of either 
cisplatin or etoposide for three days, with subsequent expo-
sure to DCA for another four days, was tested using the two 
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Figure 2 effects of DCA 10 mM on cytotoxicity of cisplatin and satraplatin against es-2 ovarian cancer cells (survival in percentage of control, mean ± standard deviation).Clinical Pharmacology:  Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
181
Cytotoxicity of dichloroacetate–platinum
SCLC lines, DMS153 and NCI-H417, respectively. These 
regimens resulted in minor sensitization of the cisplatin- and 
etoposide-pretreated cells to growth inhibition by DCA (data 
not shown).
Discussion
DCA is a generic drug that inhibits PDK and, due to its   ability 
to suppress aerobic glycolysis in favor of   mitochondrial 
  respiration, has been used medically without approval for the 
treatment of metabolic acidosis at high doses for decades.16 
After demonstration of the anticancer activity of DCA in an 
experimental animal model without apparent side effects, 
the drug was further investigated in vitro and in vivo using 
various cancer cell lines.4 Meanwhile, DCA is in use as 
an alternative anticancer drug, and a number of clinical 
  studies have progressed to different stages (registered under 
  clinicaltrials.gov).17
The anticancer activity of DCA is attributed to inhibi-
tion of PDK and suppression of the pyruvate dehydroge-
nase complex, which depresses mitochondrial functions 
that in turn provide crucial factors involved in apoptotic 
cell death.4 Production of lactic acid is thereby diminished, 
and the mitochondrial membrane potential is normalized 
  concomitant with selective activation of mitochondrial 
  potassium channels in cancer cells. These effects of DCA 
were reported to be mimicked by silencing of PDK using 
siRNA.4 In vitro   treatment of a range of cell lines resulted 
in variable   proportions of cell cycle-arrested or apoptotic 
cells depending on the tissue of origin in different studies. 
For example, in colon cancer cell lines, DCA 20 mM cause 
a selective increase in G2 phase-blocked and apoptotic cells 
after two days.6 DCA reduced lactate levels in cell culture 
supernatants and induced dephosphorylation of the E1α 
subunit of the pyruvate dehydrogenase complex in all cancer 
cell lines, leading to decreased proliferation of colorectal 
cancer but not of noncancerous cells. Recently, DCA was 
shown to promote the apoptotic machinery through inter-
action with Bcl-2.18 This drug alone produced significant 
cytotoxic effects in prostate cancer cell lines, was associ-
ated with G1 cell-cycle arrest, and apoptotic cells were 
furthermore demonstrated in DCA-treated endometrial 
cancer cells.5 It should be noted that a recent publication 
reported conflicting results, identifying higher IC50 values 
for the anticancer activity of DCA and lack of sensitivity for 
tumor cells, among others.19
Since single use of DCA may be insufficient to achieve 
significant clinical activity, combination with cytotoxic drugs 
is expected to potentiate antitumor therapy by converting 
damage to cellular components into increased apoptotic cell 
death due to reactivation of mitochondrial function in cancer 
cells. This approach was first followed in the development of 
a cisplatin coordination complex containing two axial DCA 
moieties, namely mitaplatin. However, the cytotoxic activity 
of mitaplatin only equals that of the parent drug cisplatin, 
and we found in our laboratory that DCA had synergistic 
antitumor effects that were restricted to platinum compounds 
other than cisplatin against a chemoresistant carcinoid cell 
line.11,15 DCA at concentrations #10 mM inhibited the growth 
of a large panel of pediatric tumor cell lines only moderately, 
even though phosphatidylserine was externalized and the 
Table 1 effects of combinations of selected platinum drugs with DCA 10 mM on chemosensitivity of a panel of cell lines
Cell line  Origin Inhibition IC50  
cisplatin
+ DCA  
ratio
IC50  
carboplatin
+ DCA  
ratio
IC50  
satraplatin
+ DCA  
ratio
IC50  
JM118
+ DCA   
ratio
heK293 normal  
kidney
11.1 ± 1.8 0.11 ± 0.07 0.48* 10.0 ± 3.7 1.47* 1.00 ± 0.05 1.38* 0.13 ± 0.07 1.25
DMs153 sCLC 22.5 ± 6.1 0.04 ± 0.02 1.12 0.37 ± 0.03 2.41* 0.47 ± 0.06 2.24* 0.16 ± 0.07 3.20*
nCi-417 sCLC 11.0 ± 7.1 0.19 ± 0.06 1.30* 5.10 ± 0.07 1.80* 9.8 ± 0.44 4.73* 0.87 ± 0.06 2.80*
COLO 205 Colon  
cancer
3.0 ± 1.8 11.94 ± 0.9 0.86 54.40 ± 6.6 1.19 16.7 ± 1.8 1.22 1.87 ± 0.18 1.11
TC71 ewing’s  
sarcoma
10.7 ± 6.8 0.26 ± 0.04 1.13 17.8 ± 7.7 1.08 0.83 ± 0.08 1.80* 0.09 ± 0.02 1.27*
TC252 ewing’s  
sarcoma
-22.4 ± 5.2 0.048 ± 0.008 1.19 1.25 ± 0.07 0.83 0.28 ± 0.07 1.64* 0.06 ± 0.01 1.77*
UMC-11 Carcinoid 22.2 ± 3.2 9.90 ± 0.52 1.22 13.30 ± 2.5 2.49* 3.75 ± 0.92 1.50* 0.91 ± 0.05 1.75*
h835 Carcinoid 1.0 ± 1.4 0.63 ± 0.07 0.53 20.0 ± 6.7 1.12 0.86 ± 0.04 0.5* 0.15 ± 0.05 0.31*
es-2 Ovarian 
cancer
13.0 ± 0.21 0.31 ± 0.04 1.00 6.66 ± 0.8 1.14 2.92 ± 0.08 2.33* 0.62 ± 0.02 1.32*
Notes: growth inhibition by DCA 10 mM in percentage of medium control, iC50 of cisplatin and carboplatin in µg/mL, of satraplatin and JM118 in µM; + DCA ratio lists iC50 
in medium control divided by iC50 in presence of DCA 10 mM; *P , 0.05.
Abbreviations: sCLC, small cell lung cancer; DCA, dichloroacetate.Clinical Pharmacology:  Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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mitochondrial membrane potential reduced.14 Furthermore, 
DCA abrogated the cytotoxicity of cisplatin in most cell lines 
without impairment of the in vitro stability or the cellular 
uptake of cisplatin.
In the present study, we investigated combined treatment 
of platinum complexes with DCA in a range of different cell 
lines, including HEK293 normal epithelial kidney cells. 
Supplementation of DCA in cytotoxicity assays sensitized 
tumor cells to selected platinum-based drugs, such as 
carboplatin, satraplatin, and its main metabolite, JM118, 
in addition to oxoplatin, but not cisplatin, oxaliplatin, and 
picoplatin. There was no correlation of the effects of DCA 
with the chemical structure of the compounds or oxidation 
status of the central platinum atom, respectively, since both 
the platinum (II) compounds (cisplatin, carboplatin, oxali-
platin, and picoplatin) and the platinum (IV) complexes 
(satraplatin and oxoplatin) exhibited varying effects with 
DCA. Given that DCA restores mitochondrial functions 
and facilitates apoptotic cell death, pretreatment of cancer 
cells with this drug prior to application of cytotoxic drugs 
was expected to result in synergism. Instead, preincuba-
tion of two SCLC cell lines with DCA 10 mM for three 
days followed by treatment with platinum drugs yielded 
antagonistic effects in almost all cases. Similarly, inversion 
of the treatment schedule, ie, pretreatment with cisplatin or 
etoposide and subsequent application of DCA, resulted in 
minor sensitization of the cancer cells to growth inhibition 
by DCA. Proliferation of one Ewing’s sarcoma cell line was 
stimulated by DCA, and the modulating effects of DCA 
were low in COLO 205 colon cancer cells and reversed in 
H835 carcinoid cells, with the exception of cisplatin. H835 
spherical aggregates may contain a number of hypoxic cells 
in their interior that seem to respond in a different manner 
to DCA. This is in line with a report describing growth 
stimulation by DCA in HeLa and PANC-1 cancer cell lines 
under anaerobic conditions.20
In conclusion, DCA must be present concurrently to 
sensitize cancer cells to selected platinum-based drugs, and 
pretreatment with DCA that is supposed to induce a metabolic 
switch increases drug resistance to platinum-based drugs, 
which has to be taken into account with the complementary 
use of this drug. The mechanisms leading to synergy of DCA 
with some platinum drugs, especially carboplatin, satraplatin, 
and JM118, are not clear. High doses of DCA (approximately 
50 mg/kg) are used clinically to treat metabolic acidosis, and 
biotransformation of DCA by glutathione S-transferase ζ in the 
liver is the major elimination pathway in humans.21 DCA was 
shown to suppress the expression of several cytochrome P450 
enzymes and glutathione S-transferase π1, by two- to fivefold in 
rodents.9 Therefore, DCA may downregulate drug-  metabolizing 
enzymes that inactivate platinum compounds. DCA is generally 
well tolerated and dehalogenated to monochloroacetate and 
glyoxylate in vivo before it is further catabolized to glycolate, 
glycine, oxalate, and carbon dioxide.22 Because DCA may be 
present in quite high intracellular concentrations, these products 
of drug breakdown may directly modulate the intracellular fate 
of different platinum drugs. DCA may represent a valuable 
adjunct to third-generation platinum drugs for the treatment 
of cisplatin-refractory cancer entities, such as SCLC, Ewing’s 
sarcoma, and ovarian cancer.23
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